Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension
This study demonstrates that SGLT2-I may be clinically beneficial in patients with PH by reducing all-cause mortality, RHF, and hospital admissions. Our findings support the role of SGLT2-I as a therapeutic option in PH and provide support for future randomized controlled trials using this treatment.
Authors
- Adriano R. Tonelli (ORCID: https://orcid.org/0000-0002-2321-9545)
- M. Obeidat (ORCID: https://orcid.org/0009-0008-7331-1586)
- Rashid Abdel-Razeq (ORCID: https://orcid.org/0000-0001-8928-3294)
- Aravinthan Vignarajah (ORCID: https://orcid.org/0000-0002-3758-0024)
- Nishanthi Vigneswaramoorthy
- Ala’eddien Nathir
Institutions
- University of Jordan (JO)
- Cleveland Clinic (US)
- SUNY Upstate Medical University (US)
Publication Details
- Journal
- Therapeutic Advances in Respiratory Disease
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17534666251351443
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.04